Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis

Papers of special note have been highlighted as: • of interest

References

• 1 Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers. Med. 7, 357 (2014).
  Medline CASGoogle Scholar
• 2 Abdel-Rahman O. Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials. Crit. Rev. Oncol. Hematol. doi:10.1016/j.critrevonc.2015.08.015 (2015) (Epub ahead of print).
  Google Scholar
• 3 Hodi FS, O'Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).• In this study, diarrhea was observed in 146 pts (38.4%), 43 pts (32.8%) and 26 pts (19.7%) in arms A, B and C.
  Medline CASGoogle Scholar
• 4 Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517–2526 (2011).
  Medline CASGoogle Scholar
• 5 Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. N. Engl. J. Med. 369(2), 134–144 (2013).
  Medline CASGoogle Scholar
• 6 Berger R, Rotem-Yehudar R, Slama G et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14(10), 3044–3051 (2008).
  Medline CASGoogle Scholar
• 7 Armand P, Nagler A, Weller EA et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international Phase II trial. J. Clin. Oncol. 31(33), 4199–4206 (2013).
  Medline CASGoogle Scholar
• 8 Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455–2465 (2012).
  Medline CASGoogle Scholar
• 9 Westin JR, Chu F, Zhang M et al. Safety and activity of pd1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, Phase 2 trial. Lancet Oncol. 15(1), 69–77 (2014).
  Medline CASGoogle Scholar
• 10 Abdel-Rahman O, Elhalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol. 11(17), 2471–2784 (2015).
  CASGoogle Scholar
• 11 Abdel-Rahman O, Elhalawani H, Fouad M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors; a meta-analysis. Future Oncol. doi:10.2217/FON.15.222 (2015) (In press).
  Google Scholar
• 12 Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270(5238), 985–988 (1995).
  Medline CASGoogle Scholar
• 13 Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5), 541–547 (1995).
  Medline CASGoogle Scholar
• 14 Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100(8), 4712–4717 (2003).
  Medline CASGoogle Scholar
• 15 Johnston R, Lutzky J, Chodhry A, Barkin J. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig. Dis. Sci. 54(11), 2538–2540 (2009).
  Medline CASGoogle Scholar
• 16 Lebbe C, O'Day S, Chiarion-Sileni V et al. Analysis of the onset and resolution of immune-related adverse events during treatment with ipilimumab in patients with metastatic melanoma. Presented at: Perspectives in Melanoma XII, Scheveningen, The Hague, The Netherlands, 2–4 October 2008 (Abstract O-015).
  Google Scholar
• 17 Cheng R, Cooper A, Kench J et al. Ipilimumab‐induced toxicities and the gastroenterologist. J. Gastroenterol. Hepatol. 30(4), 657–666 (2015).
  Medline CASGoogle Scholar
• 18 Gielisse EA, De Boer NK. Ipilimumab in a patient with known crohn's disease: to give or not to give? J. Crohn's Colitis 8(12), 1742–1742 (2014).
  MedlineGoogle Scholar
• 19 Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, Phase 2, dose-ranging study. Lancet Oncol. 11(2), 155–164 (2010).
  Medline CASGoogle Scholar
• 20 Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 18(2), 206–213 (2006).
  Medline CASGoogle Scholar
• 21 Berman D, Parker S, Chasalow S et al. Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide. Presented at: ASCO Annual Meeting Proceedings. IL, USA, 30 May–01 June 2008.
  Google Scholar
• 22 Kim KW, Ramaiya NH, Krajewski KM et al. Ipilimumab-associated colitis: CT findings. Am. J. Roentgenol. 200(5), W468–W474 (2013).
  MedlineGoogle Scholar
• 23 Lyall A, Vargas HA, Carvajal RD, Ulaner G. Ipilimumab-induced colitis on FDG PET/CT. Clin. Nucl. Med. 37(6), 629–630 (2012).
  MedlineGoogle Scholar
• 24 Tarhini A, Laframboise W, Petrosko P, Deamont C, Kirkwood J. Clustered genomic variants specific to patients who develop immune-related colitis after ipilimumab for prediction of toxicity. J. Clin. Oncol. 32, 5s (2014) (suppl; abstr 9024).
  MedlineGoogle Scholar
• 25 Merrill SP, Reynolds P, Kalra A, Biehl J, Vandivier RW, Mueller SW. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann. Pharmacother. 48(6), 806–810 (2014).
  MedlineGoogle Scholar
• 26 Slangen R, Van Den Eertwegh A, Van Bodegraven AA, De Boer NK. Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab. World J. Gastrointest. Pharmacol. Ther. 4, 80–82 (2013).
  MedlineGoogle Scholar
• 27 Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30(21), 2691–2697 (2012).
  Medline CASGoogle Scholar
• 28 Lin R, Yellin M, Lowy I, Safferman A, Chin K, Ibrahim R. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: prevention of gastrointestinal perforation and/or colectomy. J. Clin. Oncol. 26(15S), (2008) (suppl; abstr 9063).
  Google Scholar
• 29 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. Ann. Intern. Med. 151(4), 264–269 (2009).
  MedlineGoogle Scholar
• 30 Dersimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 7(3), 177–188 (1986).
  Medline CASGoogle Scholar
• 31 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 327(7414), 557 (2003).
  MedlineGoogle Scholar
• 32 Eggermont AM, Chiarion-Sileni V, Grob J-J et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage iii melanoma (eortc 18071): a randomised, double-blind, Phase 3 trial. Lancet Oncol. 16(5), 522–530 (2015).
  Medline CASGoogle Scholar
• 33 Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIb/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter Phase II study. J. Clin. Oncol. 30(17), 2046–2054 (2012).
  Medline CASGoogle Scholar
• 34 Ribas A, Kefford R, Marshall MA et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31(5), 616–622 (2013).
  Medline CASGoogle Scholar
• 35 Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 320–330 (2015).
  Medline CASGoogle Scholar
• 36 Kwon ED, Drake CG, Scher HI et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (ca184–043): a multicentre, randomised, double-blind, Phase 3 trial. Lancet Oncol. 15(7), 700–712 (2014).
  Medline CASGoogle Scholar
• 37 Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N. Engl. J. Med. 373(2), 123–135 (2015).
  Medline CASGoogle Scholar
• 38 Weber JS, D'angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (checkmate 037): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 16(4), 375–384 (2015).
  Medline CASGoogle Scholar
• 39 Reck M, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase 2 trial. Ann. Oncol. 24(1), 75–83 (2013).
  Medline CASGoogle Scholar
• 40 Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukoc. Biol. 94(1), 25–39 (2013).
  Medline CASGoogle Scholar
• 41 Alegre M-L, Noel PJ, Eisfelder BJ et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol. 157(11), 4762–4770 (1996).
  Medline CASGoogle Scholar
• 42 Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
  Medline CASGoogle Scholar
• 43 Abdel-Rahman O, Fouad M. Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis. Expert Rev. Anticancer Ther. 15(4), 465–475 (2015).
  Medline CASGoogle Scholar
• 44 Abdel-Rahman O, Fouad M. Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies. Expert Rev. Anticancer Ther. 14(10), 1229–1242 (2014).
  Medline CASGoogle Scholar
• 45 Abdel-Rahman O, Fouad M. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. Expert Rev. Anticancer Ther. 15(7), 847–858 (2015).
  Medline CASGoogle Scholar
• 46 Bronstein Y, Ng CS, Hwu P, Hwu W-J. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. Am. J. Roentgenol. 197(6), W992–W1000 (2011).
  MedlineGoogle Scholar
• 47 Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. (Hagerstown, Md.: 1997) 30(8), 825 (2007).
  Medline CASGoogle Scholar
• 48 Hendler R, Wu S. Risk of severe diarrhea associated with ipilimumab in cancer patients. J. Clin. Oncol. 32, 5s (2014) (suppl; abstr 9634).
  MedlineGoogle Scholar
• 49 Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372(26), 2521–2532 (2015).
  Medline CASGoogle Scholar
• 50 Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(1), 23–34 (2015).
  Medline CASGoogle Scholar
• 51 Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372(21), 2006–2017 (2015).
  MedlineGoogle Scholar